This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Melatonin (HIGH-DOSE — antioxidant / oncology / neuroprotection use)
At 20-300 mg, melatonin is no longer a sleep hormone — it is a lipid-soluble, mitochondria-accumulating antioxidant with one of the…
Aliases (4)
Overview
What is Melatonin (HIGH-DOSE — antioxidant / oncology / neuroprotection use)?
High-dose melatonin refers to gram-range or 10-200 mg dosing well above physiologic, used for antioxidant, anti-inflammatory, oncology-adjunct, and longevity protocols rather than sleep.
Key Benefits
Potent free-radical scavenging in oxidative-stress conditions, anti-inflammatory and immune-modulating effects, possible adjunctive benefit in oncology and sepsis trials, and mitochondrial protection.
Mechanism of Action
At high doses melatonin saturates MT receptors and acts primarily as a direct antioxidant — scavenging hydroxyl, peroxyl, and nitric-oxide radicals — and upregulates SOD, catalase, and glutathione peroxidase. It also stabilizes mitochondrial membranes and inhibits NF-κB signaling.
Pharmacokinetics
▸Brand options2 known
StatusOTC supplement (US, Canada, much of Asia, LatAm); Rx-only (EU/UK/AU); compounding pharmacies fill 50-300 mg custom doses in the US for off-label oncology / sleep / cluster headache use
Research Indications
Two pharmacology regimes — not the same drug at different doses
Sleep / phase-shift regime (0.3-3 mg, covered in melatonin.md): signaling. Hits MT1 (acute sleep promotion) and MT2 (SCN phase shift) at …
Direct radical scavenging — the Reiter cascade
Russel Reiter (UT San Antonio) has spent ~40 years characterizing melatonin's redox chemistry. The key insight: melatonin is one of the f…
Mitochondrial accumulation — ~100× plasma
Multiple studies (Acuña-Castroviejo, Reiter, Tan) have demonstrated that mitochondria actively concentrate melatonin to ~100× plasma leve…
Indirect antioxidant — transcriptional upregulation
Beyond direct scavenging, high-dose melatonin upregulates the endogenous antioxidant defense network via: - NRF2 pathway activation — ind…
MT3 (NQO2) — minor relevance
The historical "MT3 receptor" was reclassified as quinone reductase 2 (NQO2), an enzymatic detoxification protein that binds melatonin at…
Why this is NOT redundant with vitamin C / E / NAC / curcumin
The natural question: the user already has NAC (1,200 mg/day), vitamin C (500 mg/day), curcumin (500 mg/day), DHA omega-3 (2 g/day), and …
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
(the user's V stack — 12 mg/day): Both target mitochondrial-membrane oxidative stress; astaxanthin spans the bilayer, melatonin accumulates inside the mitoch…
(the user's V stack — 2 g DHA): DHA is the most peroxidation-susceptible fatty acid in neuronal membranes; melatonin's mitochondrial scavenging protects DHA …
(the user's V stack — 1,200 mg/day): NAC supplies cysteine for glutathione synthesis; melatonin upregulates GSS (glutathione synthetase) transcription. Diffe…
(the user's V stack — 500 mg phytosome): Both NF-κB suppressors, both NRF2 activators. Some redundancy on the transcriptional side; layered.
(the user's V stack — 3 g, transitioning to tryptophan in V5): Glycine has its own mitochondrial-glutathione-precursor role + NMDA modulation. No conflict.
(research peptide, theoretical V6+): Cardiolipin-targeted mitochondrial peptide. Highest mechanism-overlap of any compound — both concentrate at the mitochon…
(the user's V stack): Aqueous-phase scavenger; complements melatonin's lipid/mitochondrial focus.
(the user's V stack): Mg2+ is required for ATP synthase function and mitochondrial stability; cofactor support for the same compartment melatonin protects. N…
substrate-flooding the serotonin → melatonin pathway plus exogenous high-dose melatonin = excessive central serotonergic + sedative load. Specific the typica…
(benzos, Z-drugs, phenibut, GHB, opioids, gabapentinoids, alcohol): additive sedation, additive hypothermia, additive hypotension. High-dose melatonin's seda…
(CYP1A2 inhibitor): plasma melatonin AUC ↑ 17-23× — at 20 mg oral with fluvoxamine, plasma levels could approach the 300 mg dose tier. Avoid combo or use far…
similar concern, smaller magnitude.
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Day 1PK-driven acute peak per administration. Verify dose tolerated.
- Week 1Steady-state reached for most daily-dosed pharma.
- Week 2-4Therapeutic effect established; titration window if needed.
- Long-termPeriodic monitoring per drug class (labs, BP, ECG as applicable).
Side Effects & Safety 11
Side Effects
- 1Vivid / unusual / sometimes disturbing dreams: ~50-70% at ≥20 mg. Universal expectation.
- 2Morning grogginess / brain fog: ~30-50% reporting meaningful next-day fog. Higher with later-night dosing.
- 3Heavy / extended sleep (10+ hours): ~30-40% at ≥30 mg. Often desired but disqualifying for users with morning commitments.
- 4Mid-sleep awakening 4-6 hours after dose: ~20-30%, often followed by re-sleep but disrupts continuity.
- 5Mild hypothermia / cold sensation: ~15-25%.
- 6Headache post-wake: ~5-10%.
- 7Mood disruption next-day (irritability, mild dysphoria, flat affect): ~5-10%.
- 8Hypotension / dizziness at very high dose, especially first time: ~3-7%.
- 9Nausea especially without food or at high dose: ~3-5%.
- 10Daytime sedation persisting >12 hours: ~3-5%.
- 11Nightmare-driven sleep disruption (severe enough to disqualify): ~2-5%.
When to Stop
- HPG-axis suppression at chronic high dose — theoretical but genuinely concerning:
- Animal data: Robust LH/FSH suppression at very high doses (75+ mg in rodent equivalents).
- Old human data (Voordouw 1992): 75-300 mg/day in young women showed reduced LH pulsatility — the basis for melatonin's brief flirtation as an "oral contraceptive" (the B-OVAL trial). Abandoned, but signal real.
- Modern human data in young males at 5-20 mg chronic: Mostly clean. No clinically significant T/LH/FSH suppression at supplement doses.
- Modern human data at 50-300 mg chronic in young males: Essentially absent. The Spanish geriatric trials don't apply — geriatric HPG axis is fundamentally different from a 20yo's.
- For the user's PRN protocol (≤2×/week at 20-50 mg): HPG-axis concern is essentially nil. Intermittent dosing, low cumulative weekly exposure, dose tier where chronic data in young males is reassuring.
- For chronic 50+ mg daily in the user: actively avoid — the risk-reward calculus is wrong for a 20yo.
- Receptor desensitization / endogenous melatonin suppression — frequently raised, poorly supported in controlled human data. Endogenous pineal output does not appear to be downregulated by short courses of exogenous melatonin in adults. The concern at supraphysiological chronic dosing is theoretical and not consistently observed. Less alarmist in 2025-era literature than in 2005-2015 era.
- Severe morning grogginess that persists into following day — rare but occasionally reported; may indicate CYP1A2 PM status or unusual pharmacokinetics.
- Allergic reaction: very rare.
- Drug-drug interactions (see Drug interactions): meaningful for fluvoxamine, warfarin, immunosuppressants.
- Hypothermia clinically significant in users with thyroid issues / autonomic dysfunction — rare in healthy young adults.
- Reproductive caveats (theoretical fertility / spermatogenesis effects at chronic high dose) — animal data ambiguous; human data thin. Not relevant at PRN dosing.
- Theoretical immunomodulation — high-dose melatonin upregulates T-cell function in some studies, suppresses in others. Probably irrelevant in healthy adults; flag for autoimmune patients.
- First 2-3 PRN uses: titrate dose upward 10 → 20 → 30 → 50 mg across separate nights. Track sleep duration, morning alertness, dream character, next-day mood.
- First 4-8 PRN uses cumulatively: evaluate whether protocol is producing perceived recovery benefit. If null or net-negative, discontinue.
- Annual bloodwork (the user's June 2026 baseline + annual follow-up): include LH, FSH, total + free T, morning cortisol, hsCRP, CMP, lipid panel. Compare year-over-year if PRN protocol is in use.
References
Reiter et al. 2014 — Melatonin as an antioxidant: under promises but over delivers (J Pineal Res)
manifesto-style review of the cascade-scavenging mechanism; ~4 ROS per melatonin.
View StudyTan et al. 2013 — Mitochondria and chloroplasts as the original sites of melatonin synthesis (J Pineal Res)
mitochondrial concentration / synthesis hypothesis.
View StudyAcuña-Castroviejo et al. 2014 — Extrapineal melatonin: sources, regulation, and potential functions (Cell Mol Life Sci)
extrapineal mitochondrial pools and pharmacological dose context.
View StudyGalano et al. 2011 — Melatonin as a natural ally against oxidative stress: chemical insight on the AFMK/AMK cascade (J Pineal Res)
quantum-chemistry analysis of the radical scavenging cascade.
View StudyReiter et al. 2017 — Melatonin and its metabolites vs oxidative stress (Cell Mol Life Sci)
comprehensive cascade mechanism review.
View StudyHardeland 2018 — Melatonin and inflammation: story of a double-edged blade (J Pineal Res)
NF-κB / NLRP3 inflammasome modulation review.
View StudyMills et al. 2005 — Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis (J Pineal Res)
foundational meta-analysis, n=643 across 10 RCTs, 1-year mortality RR 0.66.
View StudySeely et al. 2012 — Melatonin as adjuvant cancer care with and without chemotherapy: systematic review and meta-analysis of randomized trials (Integr Cancer Ther)
expansion meta-analysis confirming Mills direction; reduced chemo toxicity signal.
View StudyWang et al. 2012 — Efficacy of melatonin as adjuvant therapy in solid tumor cancers: meta-analysis (Cancer Chemother Pharmacol)
Galley et al. 2014 — Melatonin as a potential therapy for sepsis: a phase I dose escalation study and an ex vivo whole blood model under conditions of sepsis (J Pineal Res)
dose escalation up to 100 mg, safety data.
View StudyMistraletti et al. 2015 — Melatonin reduces the need for sedation in ICU patients: a randomized controlled trial (Minerva Anestesiologica)
MELODY trial.
View StudyHenderson et al. 2018 — Melatonin in critical illness (Crit Care)
sepsis review.
View StudyGalley 2017 — A practical guide to the safe and effective use of melatonin in the ICU (Anaesthesia)
clinician-oriented review.
View StudyAndersen et al. 2016 — The safety of melatonin in humans (Clin Drug Investig)
comprehensive safety review including high-dose data.
View StudyAly et al. 2015 — Melatonin use for neuroprotection in perinatal asphyxia: a randomized controlled pilot study (J Perinatol)
neonatal HIE adjunct to hypothermia.
View StudyFulia et al. 2001 — Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin (J Pineal Res)
Robertson et al. 2013 — Melatonin augments hypothermic neuroprotection in a perinatal asphyxia model (Brain)
primate model translation.
View StudyBondy et al. 2008 onward — multiple rodent TBI / oxidative stress papers, UC Irvine line
Reiter et al. 2007-present — melatonin in CNS oxidative stress models (J Pineal Res, various)
Seifman et al. 2014 — Endogenous melatonin increases in cerebrospinal fluid of patients after severe traumatic brain injury and correlates with oxidative stress and metabolic disarray (J Cereb Blood Flow Metab)
pilot, n=12.
View StudyRezaei et al. 2017 — The effect of melatonin administration on the oxidative stress, sleep quality, and clinical outcome of patients with severe traumatic brain injury: A double-blinded randomized clinical trial
n=64, severe TBI.
View StudyNaseem & Parvez 2014 — Role of melatonin in traumatic brain injury and spinal cord injury (Sci World J)
review of mechanisms.
View StudyBabaee et al. 2015 — Melatonin treatment reduces astrogliosis and apoptosis in rats with traumatic brain injury (Iran J Basic Med Sci)
Ramlall et al. 2020 — Identification of immune-related risk factors for COVID-19 severity and the predictive role of melatonin (medRxiv / Cleveland Clinic retrospective)
propensity-matched cohort.
View StudyMousavi et al. 2022 — Melatonin effects on sleep quality and outcomes of COVID-19 patients: an open-label, randomized, controlled trial (J Med Virol)
RCT with reduced inflammatory markers.
View StudyFarnoosh et al. 2022 — Melatonin as adjunctive therapy in patients admitted to the ICU with COVID-19 (Arch Med Res)
ICU adjunct trial.
View StudyCardinali et al. 2013 — Therapeutic application of melatonin in mild cognitive impairment (Am J Neurodegener Dis)
Brzezinski et al. 2005 — Effects of exogenous melatonin on sleep: a meta-analysis (Sleep Med Rev)
dose-response at low end.
View StudyFoley & Steel 2019 — The effectiveness of melatonin for treating insomnia and improving sleep quality in adults (Sleep Med)
broad review.
View StudyVoordouw et al. 1992 — Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation (J Clin Endocrinol Metab)
historical 75-300 mg LH pulsatility data.
View StudyLuboshitzky et al. 2002 — Melatonin administration alters semen quality in healthy men (J Androl)
small study, 6 mg/day × 6 mo, mixed semen-quality findings.
View StudyHärtter et al. 2003 — Effect of fluvoxamine on melatonin pharmacokinetics (Clin Pharmacol Ther)
CYP1A2 AUC ↑17-23×.
View StudyDeMuro et al. 2000 — Bioavailability of oral melatonin: 2 mg vs 4 mg (J Clin Pharmacol)
Cohen et al. 2023 — Quantification of melatonin and serotonin in pediatric melatonin gummies (J Clin Sleep Med)
supplement quality crisis.
View StudyiHerb — Life Extension Melatonin 10 mg
primary OTC source for users in this archetype PRN protocol.
View StudyBulk Supplements — Melatonin Powder
bulk powder for chronic-high-dose users.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.